

Attorney Docket No.: DEX-0079
Inventors: Burczak and Wilkinson
Serial No.: 09/622,776
Filing Date: August 23, 2000
Page 2

In the Specification:

At page 1, please replace the paragraph at lines 5 through 10 with the following:

a1 ~~This application is the National Stage of International Application no. PCT/US99/03170, filed February 12, 1999, which is continuation of U.S. Application Serial No. 09/175,504, now abandoned, filed October 20, 1998, which is a continuation-in-part of U.S. Application Serial No. 09/111,938, now abandoned filed July 8, 1998, which claims the benefit of priority from U.S. Provisional Application Serial No. 60/075,504, filed February 23, 1998. --~~

In the Claims:

Please cancel claims 4 and 9.

Please amend the claims as follows:

- a2
1. (amended) A method of monitoring a cancer in a patient which has not metastasized for the onset of metastasis comprising:
 - (a) identifying a patient having a cancer that is not known to have metastasized;
 - (b) periodically analyzing a sample of bodily fluid from the patient for PLA₂; and
 - (c) detecting levels of PLA₂ with an enzyme level cut-off of 4.5 ng/ml, in the sample of bodily fluid obtained from the

Attorney Docket No.:

DEX-0079

Inventors:

Burczak and Wilkinson

Serial No.:

09/622,776

Filing Date:

August 23, 2000

Page 3

92
cont
patient wherein elevated levels of PLA₂ in a sample of bodily fluid are indicative of onset of metastasis of the cancer.

6. (amended) A method of diagnosing a metastatic cancer in a patient comprising:

A3
(a) obtaining a sample of biological fluid from a patient; and

(b) detecting the level of PLA₂ with an enzyme level cut-off of 4.5 ng/ml, in a sample of biological fluid wherein elevated levels of PLA₂ in the sample are indicative of metastatic cancer.

10. (amended) A method of diagnosing ovarian or testicular cancer in a patient comprising:

A4
A10
B1
(a) obtaining a sample of biological fluid from a patient; and

(b) detecting levels of PLA₂ in the sample; wherein elevated levels of PLA₂ in the sample are indicative of ovarian or testicular cancer. *comparative to which*

A5
13. (amended) A method of monitoring progression, remission, response to therapy and stabilization of prostate, breast, ovarian or testicular cancer in a patient comprising measuring PLA₂ levels with an enzyme level cut-off of 4.5 ng/ml, in biological fluids obtained from a patient at selected times wherein an increase in the measured levels of PLA₂ over time is indicative of progressive